This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Edoxaban vs low molecular weight heparin in COVID-19 hospitalized patients with atrial fibrillation (preprint)
researchsquare; 2023.
Препринт
в английский
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2489367.v1
ABSTRACT
Objective During the first wave of the SARS-CoV-2 pandemic, management of anticoagulation therapy in hospitalized patients with atrial fibrillation (AF) was simplified to low-molecular-weight heparin (LMWH), mainly due to the risk of drug-drug interactions. However, not all oral anticoagulants carry the same risk.Methods Observational, retrospective, and multicenter study that consecutively included hospitalized patients with non-valvular AF who received anticoagulant treatment with LMWH or edoxaban concomitantly with empirical therapy for COVID-19 infection.Results From March 5th to April 27th, 2020, 232 patients were included (80.3 ± 7.7 years, 50.0% men, CHA2DS2-VASc 4.1 ± 1.4; HAS-BLED 2.6 ± 1.0). Regarding COVID-19 therapy during hospitalization, patients were taking azithromycin (98.7%), hydroxychloroquine (89.7%), and ritonavir/lopinavir (81.5%). Peak D-dimer was significantly lower in the edoxaban group. The mean length of hospital stay was 14.6 ± 7.2 days and mean total follow-up (from admission to the last visit) was 31.6 ± 13.4 days. Furthermore, 12.9% of patients required admission to the intensive care unit, 18.5% of patients died, and 9.9% had a bleeding complication (34.8% major bleeding). Except for length of hospital stay, which was longer in patients taking LMWH (16.0 ± 7.7 vs 13.3 ± 6.5 days; P = 0.005), data for the remaining outcomes were similar in patients treated with edoxaban and those treated with LMWH.Conclusions Mortality rates, arterial and venous thromboembolic complications and bleedings did not significantly differ between patients with AF who received anticoagulation therapy with edoxaban or LMWH. However, the duration of hospitalization was significantly lower with edoxaban. Edoxaban had a similar therapeutic profile to LMWH and may provide additional benefit.
Полный текст:
Имеется в наличии
Коллекция:
Препринты
база данных:
PREPRINT-RESEARCHSQUARE
Основная тема:
Atrial Fibrillation
/
Venous Thromboembolism
/
COVID-19
/
Hemorrhage
Язык:
английский
Год:
2023
Тип:
Препринт
Документы, близкие по теме
MEDLINE
...
LILACS
LIS